{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:54:08Z","timestamp":1774288448262,"version":"3.50.1"},"reference-count":24,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s363235","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T10:20:11Z","timestamp":1654597211000},"page":"1911-1921","source":"Crossref","is-referenced-by-count":3,"title":["Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged \u226550 Years: A Single-Center Experience Over Two Decades"],"prefix":"10.2147","volume":"Volume 14","author":[{"given":"Simay","family":"\u00c7okgezer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu\u011frul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"Saliho\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eeniz","family":"\u00d6ng\u00f6ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Ba\u015flar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":true,"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2040620720902911","DOI":"10.1177\/2040620720902911","volume":"11","author":"Vassilakopoulos","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.mayocp.2015.07.005","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.critrevonc.2008.12.007","volume":"71","author":"Proctor","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"106311","DOI":"10.1016\/j.leukres.2020.106311","volume":"90","author":"Sykorova","year":"2020","journal-title":"Leuk Res"},{"key":"ref5","first-page":"1","volume":"39","author":"Moccia","year":"2020","journal-title":"Hematol Oncol"},{"key":"ref6","unstructured":"National Cancer Institute. Cancer stat facts: Hodgkin lymphoma. Surveillance E, and End Results (SEER) Program; 2018."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/10428194.2018.1482539","volume":"60","author":"Wr\u00f3bel","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0959-8049(97)89029-6","volume":"33","author":"Helsing","year":"1997","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","volume":"56","author":"Salvi","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2123::AID-CNCR6>3.0.CO;2-W","volume":"82","author":"Yancik","year":"1998","journal-title":"Cancer"},{"key":"ref11","first-page":"1347","volume":"2005","author":"Diehl","year":"2005","journal-title":"Hematol Basic Princ Pract"},{"key":"ref12","unstructured":"T\u00fcrkiye \u0130statistik Kurumu. Haber B\u00fclten. 2020; 33712. [Turkish]. Available from: https:\/\/data.tuik.gov.tr\/Bulten\/Index?p=Istatistiklerle-Yaslilar-2020-37227. Accessed June 1, 2022."},{"key":"ref13","unstructured":"National Cancer Institute (US). Common terminology criteria for adverse events (CTCAE).v.5.0 [5x7]. Cancer Ther Eval Progr. 2017;155:90\u201392."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref15","first-page":"1369","volume":"22","author":"Evens","year":"2008","journal-title":"Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.clml.2017.09.009","volume":"17","author":"Goyal","year":"2017","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/ajh.21910","volume":"86","author":"Carbone","year":"2011","journal-title":"Am J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10428194.2018.1522435","volume":"60","author":"Major","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00745-9","volume":"21","author":"Carter","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/hon.2675","volume":"37","author":"Cencini","year":"2019","journal-title":"Hematol Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/bmt.2010.294","volume":"46","author":"Puig","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/hon.2715","volume":"38","author":"Galli","year":"2020","journal-title":"Hematol Oncol"}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=81321","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=81321","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T10:20:16Z","timestamp":1654597216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/treatment-responses-toxicity-and-survival-in-patients-with-classical-h-peer-reviewed-fulltext-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2147\/cmar.s363235","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}